ThromboGenics plans to absorb Belgian subsidiary Thromb-X

ThromboGenics NV, a biotechnology company focused on vascular disease, announces today that it has decided to absorb Thromb-X NV, a wholly-owned subsidiary of ThromboGenics NV.

LEUVEN, Belgium | May 23, 2007 |
ThromboGenics NV (Euronext Brussels: THR), abiotechnology company focused on vascular disease, announces today that it has decidedto absorb Thromb-X NV, a wholly-owned subsidiary of ThromboGenics NV. There shall beno issuance of new shares or cash payment upon this transaction. The transaction isexpected to be approved at the next Extraordinary General Assembly in July 2007.

Thromb-X is based in Leuven, Belgium, and focuses on the research and developmentactivities of the Group. This decision will enable ThromboGenics to streamline its corporatestructure, consolidating its Belgian activities. There will be no impact on the companyoperations or financials.

After the approval of this merger by the General shareholders’ meeting, ThromboGenics NV,the Belgian holding of Group will have one subsidiary, ThromboGenics Ltd, based in Irelandwhich has one branch ThromboGenics Inc., based in the USA.ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, announces today that it has decided to absorb Thromb-X NV, a wholly-owned subsidiary of ThromboGenics NV.

SOURCE: ThromboGenics NV

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top